Table 1 Clinical and biological status of childhood pre-B2 ALL patients
Group of ALL patients | Patients ID | Age at diagnosis (Months) | Peripheral blood lymphocytes (Giga/L) | Karyotype | Fusion transcripts | Outcome |
|---|---|---|---|---|---|---|
With t(12; 21) | BACYO | 24 | 48,7 | t(12; 21) | ETV6/RUNX1 | CR1 |
GUEKE | 118 | 42,2 | t(12; 21) | ETV6/RUNX1 | CR1 | |
LECRO | 76 | 5,4 | t(12; 21) | ETV6/RUNX1 | CR1 | |
MARLE | 42 | 166 | t(12; 21) | ETV6/RUNX1 | CR1 | |
PELAD | 50 | 20 | t(12; 21) | ETV6/RUNX1 | Dead* | |
RIFEM | 76 | 216 | t(12; 21) | ETV6/RUNX1 | CR1 | |
Other karyotype abnormalities | BOILE | 18 | 2,8 | dic(9;20) | NA | CR1 |
CREBA | 180 | 11,6 | mono 21 | NA | CR1 | |
DESNA | 13 | 15,5 | rear9p | NA | CR1 | |
JUGEL | 34 | 8,5 | Hyperploidy | NA | CR1 | |
LEMAL | 48 | 56 | t(9; 22) | BCL/ABL1 | CR1 | |
MORLU | 171 | 171 | t(9; 22) | BCL/ABL1 | Dead* | |
ROSLO | 57 | 6,1 | Hyperploidy | NA | CR1 |